Skip to content
Bomb Report – Lifestyle
Author:
Precede Biosciences, Inc.
Precede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate Cancer
October 23, 2026
Muscular Dystrophy Association Launches #MDAstrong Campaign, Inviting the Neuromuscular Community to Share What “Strong” Means to Them
August 29, 2026
Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC
May 31, 2026